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SUMMARY
Diabetes is one of the most common chronic pathologies around the world, involving treatment with general clinicians, endocrinolo-
gists, cardiologists, ophthalmologists, nephrologists and a multidisciplinary team. Patients with type 2 Diabetes Mellitus (T2DM) can 
be affected by cardiac autonomic neuropathy, leading to increased mortality and morbidity. In this review, we will present current con-
cepts, clinical features, diagnosis, prognosis, and possible treatment. New drugs recently developed to reduce glycemic level presented 
a pleiotropic effect of reducing sudden death, suggesting a potential use in patients at risk.
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INTRODUCTION
Type 2 diabetes mellitus (DM2) has high morbid-
ity and mortality and great socioeconomic impact, 
having affected 150 million individuals in the year 
2000, with an expectancy of affecting 336 million by 
20301. The diabetic neuropathy, including the cardio-
vascular autonomic neuropathy (CAN), is a common 
complication of type 1 and 2 diabetes that leads to 
high mortality and morbidity2.
Patients with a CAN diagnosis have an increased 
risk of cardiovascular mortality due to acute myo-
cardial infarction and sudden death.³ Although 
CAN is an important milestone in the history of 
a DM2 patient and its screening is recommended 
by the American Diabetes Association (ADA)4, its 
present presents high variability in studies. The val-
ues found were close to 2.5% in the Diabetes Con-
trol and Complications Trial (DCCT)5; in the Oxford 
Community Diabetes Study6, the prevalence of ab-
normal results for anatomic tests was of 20.9% in 
DM1 patients and 5.8% in DM2 patients. In the Di-
aCAN7 study, the CAN prevalence was of 16.8% in 
647 DM1 patients and 22.1% in 524 DM2 patients. 
Despite the high heterogeneity in the epidemiologi-
cal findings, it is known that the prevalence of CAN 
increases with age, duration of diabetes, and inad-
equate blood glucose control, and the presence of 
hepatic steatosis in patients with a DM2 diagnosis 
of less than a year showed a strong correlation with 
anatomic lesions8. The late stages of CAN are asso-
ciated to considerable morbidity and an increase in 
mortality, related to postural hypotension, exercise 
intolerance, increase in the intraoperative instabili-
ty, the incidence of silent myocardial infarction and 
sudden death².
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PATHOGENESIS
The autonomic innervation is the primary pro-
cess in charge of controlling rate and performance. 
It must be capable of changing the rate in response 
to changes in the microenvironment. In the presence 
of sustained hyperglycemia, a neuropathic dysfunc-
tion sets in, affecting, firstly, the major and distal 
nerves and, secondly, the proximal nerves. The va-
gus nerve is the primary mechanism responsible for 
75% of all parasympathetic activity, and it is the most 
frequently damaged. Thus, the initial manifestations 
of CAN involve a parasympathetic dysfunction, with 
an anomalous predominance of the sympathetic sys-
tem9.
The precise mechanisms of cardiovascular au-
tonomic dysfunction are not yet well understood. 
Hyperglycemia increases protein glycosylation and 
causes a gradual increase in the advanced glycation 
end-products (AGEs) in the tissues. The connection 
of the AGEs with their receptors (Rage) creates a 
chronic cascade of inflammation and tissue injury, 
destroying the mechanisms for autonomic control. 
In parallel, the neural cardiovascular autonomic dys-
function perpetrates the myocardial inflammation 
and makes the tissue more excitable, thus stimulat-
ing the microvascular endothelial dysfunction and 
interstitial fibrosis10,11.
DIAGNOSIS
Heart Rate Variability (HRV)
The earliest sign for a CAN diagnosis is the reduc-
tion of HRV. The heterogeneity with each heartbeat 
is regulated by a balance between the sympathetic 
and parasympathetic activities in response to a bas-
al metabolic rate. In healthy individuals, the HRV is 
high. The reduction of HRV is linked to the severity 
and duration of the DM212.
For a diagnosis, the American Diabetes Associ-
ation (ADA) task force recommends the analysis of 
HRV from the 24-hour Holter results13. The HRV in-
dicators are: RR intervals; standard deviations of all 
normal RR (SDNN) during the recording; square root 
of the average square of the differences between con-
secutive RR intervals (RMSSD); and the percentage 
of NN intervals with a difference of over 50 millisec-
onds in relation to the previous interval (pNN50). 
The RMSSD and the pNN50 are associated with a 
high-frequency potency (0.15-0.4 Hz) and, thus, to 
the parasympathetic activity, while the SDNN is cor-
related to a low-frequency potency (0.04-0.15 Hz), 
reflecting the baroreceptor activity, an index of sym-
pathetic and parasympathetic activities3,14.
The CAN diagnosis using the 24-hour Holter re-
quires an abnormal result in at least two of the fol-
lowing six parameters: SDNN < 50 ms, RMSSD < 15 
ms, PNN50 < 0.75%, LF < 300 ms2, HF < 300 ms2 15,16. 
Ewing Test
This is the most classic and cheapest method of 
diagnosis, with a high reproducibility16. The CAN 
must be assessed by five standardized tests — three 
of them for a parasympathetic evaluation: responses 
of the heart rate to deep breathing (E/I ratio), to the 
orthostatic position (30s/15s ratio), and the Valsalva 
maneuver. The other two tests evaluate the sympa-
thetic function: responses to arterial pressure when 
rising and handgrip. The results for each test must 
be 0 if standard; 0.5 if borderline;  1 if abnormal. A 
score ≥ 2 classifies the patient as CAN +17. 
Heart Rate Turbulence (HRT)
The Heart Rate Turbulence is a method first de-
scribed by Schmidt et al.18, in 1999. It consists of two 
analysis: the beginning of the turbulence (TI) and 
the turbulence slop (ST), both extracted from the 24-
hour Holter records. It reflects the fluctuations of 
the rearranging sinus cycle after a single ventricular 
ectopic beat (VBP)18. The TI indicates the initial accel-
eration of the sinus rhythm, while the ST reflects the 
late deceleration stage of the sinus rhythm. When 
the TI is greater than 0 or the ST lower than 2.5 ms/
RR, the diagnosis is of CAN +16. The TFC is a phenom-
enon present in low-risk patients of ischemic heart 
disease. The absence of this phenomenon indicates a 
significantly increased risk of sudden death. 
CLINICAL CHARACTERISTICS
Exercise Intolerance
The autonomic dysfunction can also lead to exer-
cise intolerance with a disproportionate increase in 
heart rate and arterial pressure during exercise, a 
reduction of the systolic volume, and slow recovery.
A late finding is a tachycardia at rest: A heart rate 
of approximately 100 beats per minute per minute 
(bpm) or more reflects a relative increase in the sym-
pathetic tone, associated, to parasympathetic vagus 
damage. However, confounding factors, such as ane-
mia, dehydration, and hyperthyroidism, must be 
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ruled out. A fixed heart rate that does not respond to 
exercises of moderate intensity, stress, or sleepiness 
indicates an almost total cardiac denervation and is 
an indicator of severe CAN19,20. 
Postural Hypertension
Some DM2 patients might present orthostatic 
hypotension, i.e., a reduction of over 20 mmHg in 
systolic arterial pressure and 10 mmHg in diastolic 
arterial pressure when rising. This finding occurs 
due to sympathetic vasomotor denervation, causing 
a reduction of the vasoconstriction capacity in the 
peripheral vascular beds. The symptoms associated 
with orthostatic hypotension include visual darken-
ing, weakness, and, in more severe cases, syncope 
when rising. These events may be aggravated by sev-
eral medications, such as diuretics, vasodilators, and 
tricyclic antidepressants11,17.
Healthy individual present a reduction of the arte-
rial pressure during sleep. CAN patients can present, 
in the 24-hour map, a low decrease of the nocturnal 
arterial pressure (lower than 10%), contributing to 
left ventricular hypertrophy a fatal and non-fatal car-
diac events21.
Imaging Exam
The MIBG (metaiodobenzylguanidine) is a 
non-metabolized marker, analogous of the norepi-
nephrine, useful for the assessment of post-gan-
glionic neural fibers. Several studies have shown a 
decrease in the MIBG uptake in CAN patients. Some 
studies have shown a higher sensitivity of MIBG 
when compared with autonomic tests22. When CAN 
is present, the MIBG scintigraphy shows a lower up-
take, especially in posterior and inferior segments 
of the left ventricle, up to the total absence of MIBG 
capitation in the advanced CAN.
PROGNOSIS
A meta-analysis with over 2,900 patients showed 
that mortality for a period of up to ten years was of 
30.4% in diabetic patients with CAN, detected through 
the reduction of HRV, and 13.4% in those with no signs 
of CAN through HRV10. Whitsel et al.23 demonstrated 
that patients with a CAN diagnosis presented a signif-
icant risk of prolonged QT intervals, which are associ-
ated with sudden deaths. This meta-analysis showed 
2.3 times increase in the risk of prolonged QT interval 
in patients with diabetes and CAN.
Another publication of the Diad study showed 
that the CAN is an important predictor for silent 
myocardial ischemia, which was found in 22% of the 
asymptomatic DM2 patients. In addition, during ex-
ercise, diabetes patients with CAN presented a delay 
in the angina pain, even though the ischemic process 
was already underway, with a predisposition for pro-
longed ischemia25. 
Some trials have suggested that sudden death is 
the second or first most common cause of death for 
DM2 patients. As an example, we can mention the 
subanalysis of the Tecos study, which showed that 
sudden death was the primary cause of death of car-
diovascular origin (27%), followed by AMI/CVA (21%), 
and heart failure (12%)26. In the Empa-REG study, sud-
den death was also the leading cause of death with a 
cardiovascular origin (29.9%)27. In the Savor-Timi 53 
study, 45% of deaths due to cardiovascular origins 
were sudden deaths28. Thus, CAN must be actively 
investigated in DM2 patients. 
CLASSIFICATION
The Ewing tests are the golden standard for CAN 
diagnosis. The reference values change according 
to age. A single test with alterations already raises 
the possibility of CAN. Two or more tests with alter-
ations are a definite indicator of CAN. CAN present 
only after a HRV assessment is named as subclinical, 
while the presence of orthostatic hypotension im-
plies severe CAN29. 
TREATMENT
The best chance for intervention and changes of 
prognostics for a CAN patient is the early diagnosis. 
The treatment is based on non-pharmacological treat-
ments that include weight loss and improvements 
to insulin resistance, since both are associated with 
sympathetic hyperactivity, and exercises must be of 
low to moderate intensity30. Pharmacological mea-
sures, such as ACE inhibitors and beta-blockers, can 
contribute to the attenuation of CAN symptoms4,31. 
Therapies whose focus is, exclusively, the action of 
the sympathetic nervous system still require further 
studies, such as (i) hyperstimulation of the vagus 
nerve; (ii) renal sympathetic ablation; (iii) resection 
of the carotid body; and (iv) electrical stimulation of 
the baroreceptor.
Two classes of drugs for DM2 treatment, iSGLT2, 
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and aGLP-1, have shown a reduction in mortality 
due to cardiovascular disease using mechanisms 
not often linked to coronary artery disease. In a 
non-pre-specified analysis of the Empa-REG27, it was 
suggested that: among patients included in the study 
who suffered a fatal cardiovascular event, 137 (5.3%) 
were in the placebo group, while 90 (3.8%) were be-
ing treated with 10 mg/d empagliflozin and 82 (3.5%) 
with 25 mg/d empagliflozin. Sudden death was the 
cause of death for 38 patients in the placebo group, 30 
in the 10 mg/d empagliflozin group, and 23 in the 25 
mg/d empagliflozin group. Thus, sudden death was 
the cause for 1.6% of all deaths in the placebo group, 
against 1.1% in the group treated with empagliflozin, 
which represented a reduction of 31.25% in deaths 
by sudden death in the empagliflozin group. Studies 
using animals have demonstrated the action of the 
iSGLT2 in reducing the sympathetic hyperactivity. 
In another sub analysis also not pre-specified in 
the Leader32 study, 278 patients progressed to death 
in the placebo group, against 219 patients in the 
treated group. Of these, sudden death was the cause 
of death for 74 (1.6%) of patients in the placebo group, 
against 51 (1,1%) in the liraglutide group, represent-
ing a 31.25% reduction in deaths by sudden death.  
Thus, these two classes of drugs, iSGLT2 and 
aGLP1, are found to be possible attenuators of sud-
den death, perhaps due to their, at least partial, im-
pact on the autonomic nervous system. 
CONCLUSION
CAN is a frequent and important diagnosis 
achieved through the screening test recommend-
ed by the ADA. Due to its prognostic importance in 
DM2, the risk of sudden death and myocardial in-
farction and the possibility of treatment must not be 
neglected.
RESUMO 
Diabetes é uma das mais frequentes patologias crônicas em todo o mundo, cujo tratamento envolve uma equipe multidisciplinar, 
médicos generalistas, endocrinologistas, cardiologistas, nefrologistas e oftalmologistas. Pacientes com diabetes mellitus tipo 2 (DMT2) 
podem apresentar neuropatia autonômica cardíaca (NAC), levando a aumento de mortalidade e morbidade. Nesta revisão, apre-
sentaremos atuais conceitos, características clínicas, diagnóstico, prognóstico e possíveis tratamentos. Novas drogas recentemente 
desenvolvidas para redução de níveis glicêmicos apresentaram efeito pleiotrópico de redução de morte súbita, sugerindo um potencial 
uso neste perfil de pacientes.
PALAVRAS-CHAVE: Diabetes mellitus. Neuropatias diabéticas. Morte súbita.
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